Latest Headlines

Latest Headlines

Concordia scores ex-Big Pharma drugs in $1.2B Covis buyout

Concordia Healthcare is snatching up Covis Pharma's pharma and injectables units for $1.2 billion in cash, beefing ups its generics portfolio and riding the recent wave of pharma M&A.

Patheon strikes again; deal for Agere its second in a week

Just days after saying it was buying contract manufacturer IRIX Pharmaceuticals to get its expertise in making difficult APIs, North Carolina contract development and manufacturing company Patheon has snapped up yet another competitor, this one a specialist in bioavailability.

FDA approves novel CPR system, just after Zoll acquires its maker

The U.S. Food and Drug Administration has approved the ResQCPR System to perform cardiopulmonary resuscitation (CPR) on cardiac arrests patients. The CPR system is from startup Advanced Circulatory Systems, which was acquired for an undisclosed amount by Zoll Medical in January.

China's Mindray jumps on acquisition rumor involving state-owned investment firm

The share price of China's Mindray Medical rose 16% last week on the New York Stock Exchange amid rumors that it will be taken over by private equity firms, including the country's state-owned investment company.

Bristol-Myers' cancer meds are $15B bait for a big, deal-hungry buyer

As AbbVie's $21 billion deal to buy Pharmacyclics shows, drugmakers aren't scared to shell out for cancer drugs--and they're not worried about pricing pressure holding their purchases back. Could PD-1 pioneer Bristol-Myers Squibb be next?

Alkermes ditches some Elan remnants and bears down on its pipeline

Alkermes is selling off a manufacturing plant in a deal worth up to $170 million, cashing out of some royalty streams to better invest in its late-stage pipeline of new therapies.

Patheon snags another CMO amid its global expansion

Contract drug developer Patheon, a year removed from a $2.6 billion merger, is expanding its manufacturing footprint with another acquisition, buying up a South Carolina specialist.

AbbVie paid a 'lofty,' 'staggering,' 'astronomical' price for Pharmacyclics. But was it too much?

It's just Friday, but the Monday morning quarterbacking on AbbVie's Pharmacyclics buy is in full swing. Did AbbVie overpay at $21 billion? Should it have let Johnson & Johnson take the prize instead? Does the rich deal for Pharmacyclics spell trouble for pharmas looking to make biotech buys? And really, did AbbVie overpay?

Mallinckrodt ponies up $2.3B for Ikaria and its neonatal respiratory med

Mallinckrodt will slap down $2.3 billion to buy Ikaria, a privately held drug company, and its respiratory med for babies in neonatal ICUs. The deal will help Mallinckrodt grow its hospital drugs business, with a $150 million boost to revenue this year.

Mallinckrodt to buy Ikaria for $2.3B in a drug-device combination play

Pharma company Mallinckrodt will scoop up Ikaria, the maker of a drug-device combination product to help newborns suffering from respiratory failure breathe better.